Drug
US-licensed Humira®
US-licensed Humira® is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_3
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_1
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
NCT05108259
completedphase_1
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
NCT03970824
completedphase_1
MSB11022 in Healthy Subjects
NCT03014947
completedphase_3
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
NCT02137226
Clinical Trials (4)
Showing 4 of 4 trials
NCT05108259Phase 1
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
NCT03970824Phase 1
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
NCT03014947Phase 1
MSB11022 in Healthy Subjects
NCT02137226Phase 3
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4